This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2012 Apr;27(4):473.

doi: 10.1002/mds.24914.

Does chromatin modulation provide the first wet biomarker for Huntington's disease?

Ralf Reilmann¹

Affiliations

Affiliation

¹ EHDN Huntington Center Münster & EHDN Neuroprotective Therapy Working Group, Department of Neurology, University Clinic Muenster, Westfaelische-Wilhelms University of Muenster, Albert-Schweitzer Campus 1, Muenster, Germany.

PMID: 22590715
DOI: 10.1002/mds.24914

Comment

Does chromatin modulation provide the first wet biomarker for Huntington's disease?

Ralf Reilmann. Mov Disord. 2012 Apr.

. 2012 Apr;27(4):473.

doi: 10.1002/mds.24914.

Author

Ralf Reilmann¹

Affiliation

¹ EHDN Huntington Center Münster & EHDN Neuroprotective Therapy Working Group, Department of Neurology, University Clinic Muenster, Westfaelische-Wilhelms University of Muenster, Albert-Schweitzer Campus 1, Muenster, Germany.

PMID: 22590715
DOI: 10.1002/mds.24914

No abstract available

PubMed Disclaimer

Comment on

Transcriptional modulator H2A histone family, member Y (H2AFY) marks Huntington disease activity in man and mouse.
Hu Y, Chopra V, Chopra R, Locascio JJ, Liao Z, Ding H, Zheng B, Matson WR, Ferrante RJ, Rosas HD, Hersch SM, Scherzer CR. Hu Y, et al. Proc Natl Acad Sci U S A. 2011 Oct 11;108(41):17141-6. doi: 10.1073/pnas.1104409108. Epub 2011 Oct 3. Proc Natl Acad Sci U S A. 2011. PMID: 21969577 Free PMC article. Clinical Trial.

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Wiley